Navigation Links
Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat

Newton, MA (PRWEB) December 05, 2012

Topokine Therapeutics has announced that the first subject has been dosed in a repeat-dose, healthy volunteer study of XAF5 Gel, a skin cream for local reduction of excess subcutaneous fat (lipohypertrophy). The study is assessing the safety and tolerability of repeat doses of XAF5 Gel at three concentrations. The study is also quantifying the effects of XAF5 on subcutaneous adipose tissue.

“We are excited to enter clinical development with the first non-invasive, local drug therapy to reduce lipohypertrophy,” said Topokine’s Chief Scientific Officer, Michael Singer, MD, PhD. “We hope to provide a convenient and effective alternative to surgery and injections.”

XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

“Topokine’s preclinical data are promising,” said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Company’s Scientific Board of Advisors. “A skin cream that reduces subcutaneous fat would be an attractive proposition for patients and physicians alike.”

The company expects to report top-line results in the first half of 2013.

About Topokine and XAF5 Gel
Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

Forward-Looking Statements
This press release contains forward-looking statements regarding the development of XAF5. These statements are based on Topokine’s current beliefs and expectations, but actual results may differ.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
2. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
3. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
4. The Scientist Proudly Announces the Top 10 Innovations of 2012
5. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
6. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
7. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
10. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
11. BioRestorative Therapies Announces Launch of New Website
Post Your Comments:
(Date:12/1/2015)... ... , ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas Fertility Center as ... lab procedures as well as continue his research efforts into the emerging technologies of ... New Zealand to bring home a High Complexity Clinical Laboratory Director named Tex,” says ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
(Date:11/30/2015)... Spherix Incorporated (Nasdaq: SPEX ) an ... and monetization of intellectual property, today provided an ... to create shareholder value. Anthony ... on published reports, the total addressable market of ... Spherix will seek to secure fair and reasonable ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
Breaking Biology News(10 mins):